DD282229A5 - Verfahren zur herstellung von therapeutischen acyclischen nucleosiden - Google Patents

Verfahren zur herstellung von therapeutischen acyclischen nucleosiden Download PDF

Info

Publication number: DD282229A5
Authority: DD; German Democratic Republic
Prior art keywords: compound; formula; group; amino; active ingredient
Prior art date: 1987-08-15

Application number

DD88318867A

Other languages

German (de)

English (en)

Inventor

Thomas A Krenitzsky

Lilia M Beauchamp

Original Assignee

��@��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-15

Filing date

1988-08-12

Publication date

1990-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10622363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD282229(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-08-12 Application filed by ��@��@��@��k�� filed Critical ��@��@��@��k��

1990-09-05 Publication of DD282229A5 publication Critical patent/DD282229A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 25
238000002360 preparation method Methods 0.000 title claims abstract description 8
230000001225 therapeutic effect Effects 0.000 title abstract description 5
239000002777 nucleoside Substances 0.000 title abstract description 4
150000001875 compounds Chemical class 0.000 claims abstract description 74
150000003839 salts Chemical class 0.000 claims abstract description 23
-1 (purin-9-yl) -methoxy Chemical group 0.000 claims description 27
125000003277 amino group Chemical group 0.000 claims description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
125000006239 protecting group Chemical group 0.000 claims description 6
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
239000004474 valine Substances 0.000 claims description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
229960000310 isoleucine Drugs 0.000 claims description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
230000009466 transformation Effects 0.000 claims description 2
238000000844 transformation Methods 0.000 claims description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 abstract description 28
229960004150 aciclovir Drugs 0.000 abstract description 26
238000011282 treatment Methods 0.000 abstract description 12
238000011321 prophylaxis Methods 0.000 abstract description 8
150000002148 esters Chemical class 0.000 abstract description 4
150000001413 amino acids Chemical class 0.000 abstract description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract description 2
208000029433 Herpesviridae infectious disease Diseases 0.000 abstract 2
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 abstract 1
239000002212 purine nucleoside Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 59
239000004480 active ingredient Substances 0.000 description 48
238000009472 formulation Methods 0.000 description 42
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
239000000243 solution Substances 0.000 description 25
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 24
239000007787 solid Substances 0.000 description 20
239000000725 suspension Substances 0.000 description 19
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 18
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
239000004615 ingredient Substances 0.000 description 12
239000002775 capsule Substances 0.000 description 11
239000007788 liquid Substances 0.000 description 11
239000003826 tablet Substances 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
230000000840 anti-viral effect Effects 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
229960000549 4-dimethylaminophenol Drugs 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 7
239000003054 catalyst Substances 0.000 description 7
239000008101 lactose Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
239000003921 oil Substances 0.000 description 7
239000000843 powder Substances 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
125000002252 acyl group Chemical group 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000000460 chlorine Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
239000000126 substance Substances 0.000 description 5
CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 4
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
239000006071 cream Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
239000000829 suppository Substances 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
229960004295 valine Drugs 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000007327 hydrogenolysis reaction Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000006072 paste Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000047 product Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
JSHXJPFZKBRLFU-JQWIXIFHSA-N (2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 JSHXJPFZKBRLFU-JQWIXIFHSA-N 0.000 description 2
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000701027 Human herpesvirus 6 Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
206010038997 Retroviral infections Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
125000003435 aroyl group Chemical group 0.000 description 2
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007907 direct compression Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000005187 foaming Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
VIOAGOMGEZTUHG-UHFFFAOYSA-L magnesium;2-hydroxyacetate;octadecanoate Chemical compound [Mg+2].OCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O VIOAGOMGEZTUHG-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000013160 medical therapy Methods 0.000 description 2
239000000155 melt Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000006916 nutrient agar Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
238000003797 solvolysis reaction Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
CANZBRDGRHNSGZ-LLVKDONJSA-N (2r)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-LLVKDONJSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
CANZBRDGRHNSGZ-UHFFFAOYSA-N 3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)C(C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-UHFFFAOYSA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000004358 Butane-1, 3-diol Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
206010019972 Herpes viral infections Diseases 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
241000700159 Rattus Species 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001294 alanine derivatives Chemical class 0.000 description 1
238000006136 alcoholysis reaction Methods 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
229940089206 anhydrous dextrose Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000005002 aryl methyl group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
238000004422 calculation algorithm Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
BQIVJVAZDJHDJF-LURJTMIESA-N ethyl (2s)-2-amino-3-methylbutanoate Chemical compound CCOC(=O)[C@@H](N)C(C)C BQIVJVAZDJHDJF-LURJTMIESA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000002154 ionophoretic effect Effects 0.000 description 1
150000002519 isoleucine derivatives Chemical class 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000011670 long-evans rat Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
229940054534 ophthalmic solution Drugs 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
150000003212 purines Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
238000009491 slugging Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
208000025889 stromal keratitis Diseases 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000048 toxicity data Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD88318867A 1987-08-15 1988-08-12 Verfahren zur herstellung von therapeutischen acyclischen nucleosiden DD282229A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB878719367A GB8719367D0 (en)	1987-08-15	1987-08-15	Therapeutic compounds

Publications (1)

Publication Number	Publication Date
DD282229A5 true DD282229A5 (de)	1990-09-05

Family

ID=10622363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD88318867A DD282229A5 (de)	1987-08-15	1988-08-12	Verfahren zur herstellung von therapeutischen acyclischen nucleosiden

Country Status (13)

Country	Link
US (1)	US4957924A (lt)
AP (1)	AP9000238A0 (lt)
AT (1)	ATE116648T1 (lt)
CA (1)	CA1340083C (lt)
DD (1)	DD282229A5 (lt)
DE (2)	DE19575021I2 (lt)
ES (1)	ES2065914T3 (lt)
GB (1)	GB8719367D0 (lt)
HK (1)	HK39595A (lt)
HU (1)	HU210815A9 (lt)
LT (1)	LT2063B (lt)
PH (2)	PH29942A (lt)
ZA (1)	ZA885995B (lt)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458772B1 (en)	1909-10-07	2002-10-01	Medivir Ab	Prodrugs
GB8725939D0 (en) *	1987-11-05	1987-12-09	Wellcome Found	Therapeutic compounds
GB8829571D0 (en) *	1988-12-19	1989-02-08	Wellcome Found	Antiviral compounds
US5677308A (en) *	1996-12-19	1997-10-14	Lerner; A. Martin	Method for alleviating spasmodic torticollis
US5872123A (en)	1997-02-18	1999-02-16	Lerner; A. Martin	Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6399622B1 (en)	1997-02-18	2002-06-04	A. Martin Lerner	Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6537997B1 (en)	1997-02-18	2003-03-25	A. Martin Lerner	Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
PT988304E (pt) *	1997-08-15	2001-10-31	Medivir Ab	Analogos de nucleosidos tais como os antivirais que contem inibidores de transcritase reversa retroviral e de adn-polimerase do virus da hepatite b (hbv)
US20020128301A1 (en) *	1998-02-13	2002-09-12	Medivir AB	Non-nucleoside reverse transcriptase inhibitors
PT2415776T (pt)	1998-08-10	2016-07-07	Novartis Ag	Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
US6444652B1 (en)	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6107303A (en) *	1999-03-15	2000-08-22	Demarco; Charlene C.	Treatment of Epstein Barr infection
US6448256B1 (en)	1999-05-24	2002-09-10	University Of Massachusetts	Antibiotic prodrugs
GB0010446D0 (en) *	2000-04-28	2000-06-14	Glaxo Wellcome Kk	Pharmaceutical formulation
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
US6787526B1 (en)	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
EP1736478B1 (en) *	2000-05-26	2015-07-22	IDENIX Pharmaceuticals, Inc.	Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) *	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20030212051A1 (en) *	2001-04-06	2003-11-13	Polli James E	Bile acid containing prodrugs with enhanced bioavailabilty
HUP0500753A3 (en) *	2001-09-07	2006-05-29	Teva Pharma	Crystalline forms of valacyclovir hydrochloride
EP1435974A4 (en) *	2001-09-28	2006-09-06	Idenix Cayman Ltd	METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
WO2003040145A1 (en) *	2001-11-05	2003-05-15	Glaxo Group Limited	Anhydrous crystal form of valaciclovir hydrochloride
CN1307177C (zh)	2001-11-14	2007-03-28	特瓦制药工业有限公司	伐昔洛韦的合成与纯化
AU2002365234B2 (en) *	2001-12-14	2009-01-29	Pharmasset Inc	N4-acylcytosine nucleosides for treatment of viral infections
CA2470938A1 (en)	2001-12-20	2003-07-03	Beth Israel Deaconess Medical Center	Treatment of ebv and khsv infection and associated abnormal cellular proliferation
SE521676C2 (sv) *	2002-01-02	2003-11-25	Dilafor Ab	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
JP2005522443A (ja) *	2002-02-14	2005-07-28	フアーマセツト・リミテツド	改変フッ素化ヌクレオシド類似体
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
WO2004000265A2 (en) *	2002-06-24	2003-12-31	Ranbaxy Laboratories Limited	Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
TW200500375A (en)	2002-06-28	2005-01-01	Idenix Cayman Ltd	Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
PL374792A1 (en)	2002-06-28	2005-10-31	Idenix (Cayman) Limited	2' and 3'-nucleoside prodrugs for treating flaviviridae infections
CN1678326A (zh)	2002-06-28	2005-10-05	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) *	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en)	2002-06-28	2007-10-26	Idenix Cayman Ltd	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) *	2002-08-06	2005-12-01	Idenix Pharmaceuticals Inc	Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US20050043329A1 (en) *	2002-09-06	2005-02-24	Shlomit Wizel	Crystalline forms of valacyclovir hydrochloride
EP1572095B1 (en) *	2002-09-13	2015-06-10	Novartis AG	Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains
CN1319972C (zh) *	2002-10-16	2007-06-06	特瓦制药工业有限公司	在盐酸伐昔洛韦结晶中减少残留醇类物质的方法
EP1551838B1 (en) *	2002-10-16	2006-08-09	Teva Pharmaceutical Industries Ltd.	Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) *	2002-10-16	2005-03-17	Ben-Zion Dolitzky	Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
LT1576138T (lt)	2002-11-15	2017-06-26	Idenix Pharmaceuticals Llc	2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
TWI332507B (en) *	2002-11-19	2010-11-01	Hoffmann La Roche	Antiviral nucleoside derivatives
AU2003289995A1 (en) *	2002-12-09	2004-06-30	Texcontor Etablissement	Anhydrous crystalline form of valacyclovir hydrochloride
CN1742018A (zh) *	2002-12-10	2006-03-01	弗·哈夫曼-拉罗切有限公司	抗病毒的核苷衍生物
AU2003300901A1 (en)	2002-12-12	2004-06-30	Idenix (Cayman) Limited	Process for the production of 2'-branched nucleosides
NZ540913A (en) *	2002-12-23	2008-02-29	Idenix Cayman Ltd	Process for the production of 3'-nucleoside prodrugs
DK1583542T3 (da)	2003-01-14	2008-09-22	Gilead Sciences Inc	Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
WO2004084453A2 (en) *	2003-03-20	2004-09-30	Microbiologica Quimica E Farmaceutica Ltd.	METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
KR20060015542A (ko) *	2003-04-28	2006-02-17	이데닉스 (케이만) 리미티드	산업 규모의 뉴클레오시드 합성
HUE029877T2 (en)	2003-05-30	2017-04-28	Gilead Pharmasset Llc	Modified fluorinated nucleoside analogues
WO2004106338A1 (en) *	2003-05-30	2004-12-09	Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S.	Novel crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko)	2003-06-02	2008-12-02	테바 파마슈티컬 인더스트리즈 리미티드	발라시클로비르 히드로클로라이드의 신규한 결정질 형태
WO2005003374A2 (en) *	2003-06-30	2005-01-13	Idenix (Cayman) Limited	SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES
US20050025839A1 (en) *	2003-07-28	2005-02-03	Polli James Edward	Formulation approach to enhance transporter-mediated drug uptake
US20050137141A1 (en) *	2003-10-24	2005-06-23	John Hilfinger	Prodrug composition
US20070167353A1 (en) *	2003-10-24	2007-07-19	John Hilfinger	Prodrug composition
US7253175B2 (en) *	2003-11-13	2007-08-07	Barnet Liberman	Method for treating athlete's foot
US7754718B2 (en)	2004-05-05	2010-07-13	Yale University	Antiviral helioxanthin analogs
CA2571675A1 (en) *	2004-06-23	2006-01-05	Idenix (Cayman) Limited	5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh)	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
CA2578750A1 (en) *	2004-09-04	2006-03-16	Teva Pharmaceutical Industries, Ltd.	A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
US8492539B2 (en)	2004-09-14	2013-07-23	Gilead Pharmasset Llc	Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US20060178512A1 (en) *	2005-02-04	2006-08-10	Cheruthur Govindan	Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) *	2005-05-25	2012-03-15	Lilly Co Eli	Cyclopropancarbonsäureester von acyclovir
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
EP1746098A1 (en) *	2005-07-21	2007-01-24	SOLMAG S.p.A.	Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) *	2005-11-14	2007-05-17	Khunt Mayur D	Valacyclovir process
ES2422290T3 (es)	2005-12-23	2013-09-10	Idenix Pharmaceuticals Inc	Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
GB0605344D0 (en) *	2006-03-17	2006-04-26	Pliva Istrazivanje I Razvoj D	Pharmaceutically acceptable salts and polymorphic forms
EP2068906B1 (en) *	2006-09-19	2012-08-01	Sungkyunkwan University Foundation for Corporate Collaboration	Antiviral agent against animal viruses
US20080167325A1 (en) *	2006-12-27	2008-07-10	Bs Praveen Kumar	Valacyclovir compositions
CA2675134A1 (en) *	2007-01-12	2008-07-24	Biomarin Pharmaceutical Inc.	Pterin analogs
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US20080281099A1 (en) *	2007-05-07	2008-11-13	Mayur Devjibhai Khunt	Process for purifying valacyclovir hydrochloride and intermediates thereof
US20090076039A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched valacyclovir
RU2470642C2 (ru) *	2008-01-03	2012-12-27	Байомарин Фармасьютикл Инк.	Аналоги птерина для лечения состояния, чувствительного к вн4
WO2009120358A1 (en) *	2008-03-27	2009-10-01	Nektar Therapeutics	Oligomer-nitrogenous base conjugates
TW200946541A (en) *	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
NZ593649A (en) *	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Nucleoside analogs
PA8855601A1 (es)	2008-12-23	2010-07-27		Forformidatos de nucleósidos
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TWI583692B (zh) *	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
SG184324A1 (en)	2010-03-31	2012-11-29	Gilead Pharmasset Llc	Nucleoside phosphoramidates
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
CA2818853A1 (en)	2010-11-30	2012-06-07	Gilead Pharmasset Llc	2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
CN102584825B (zh) *	2011-01-17	2014-04-02	四川科伦药物研究有限公司	一种合成盐酸伐昔洛韦的方法
US20140296520A1 (en) *	2011-11-25	2014-10-02	Piramal Enterprises Limited	Process for the preparation of valacyclovir hydrochloride
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
US20140100238A1 (en)	2012-10-04	2014-04-10	Ohio State University	Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
TW201429475A (zh) *	2013-01-29	2014-08-01	Li-Ly Hsiao	使用抗病毒藥治療末稍神經病變之疾病
US20140213600A1 (en) *	2013-01-29	2014-07-31	Lily Hsiao	Medicament for treating peripheral neuropathies
PT3038601T (pt)	2013-08-27	2020-06-30	Gilead Pharmasset Llc	Formulação combinada de dois compostos antivirais
CN115745997A (zh) *	2022-11-30	2023-03-07	湖北省宏源药业科技股份有限公司	一种高纯度伐昔洛韦杂质h制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1561380A (en) *	1976-03-01	1980-02-20	Wellcome Found	Esters of hydroxyalkoxyalkyl purines their preparation and pharmaceutical compositions containing them
US4199574A (en) *	1974-09-02	1980-04-22	Burroughs Wellcome Co.	Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB1523865A (en) *	1974-09-02	1978-09-06	Wellcome Found	Purine compunds and salts thereof
US4287188A (en) *	1977-02-24	1981-09-01	Burroughs Wellcome Co.	Purine derivatives
US4457919A (en) *	1980-03-14	1984-07-03	Newport Pharmaceutical International, Inc.	Method of imparting immunomodulating, antiviral or antitumor activity
AU564576B2 (en) *	1981-09-24	1987-08-20	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Purine derivatives
NL8202626A (nl) *	1982-06-29	1984-01-16	Stichting Rega V Z W	Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
US4745119A (en) *	1982-10-14	1988-05-17	Burroughs Wellcome Co.	Method for using purine derivatives
US4695570A (en) *	1982-10-14	1987-09-22	Burroughs Wellcome Co.	Antiviral compound use

1987
- 1987-08-15 GB GB878719367A patent/GB8719367D0/en active Pending
1988
- 1988-08-04 US US07/228,377 patent/US4957924A/en not_active Expired - Lifetime
- 1988-08-12 DD DD88318867A patent/DD282229A5/de unknown
- 1988-08-12 ZA ZA885995A patent/ZA885995B/xx unknown
- 1988-08-12 DE DE1995175021 patent/DE19575021I2/de active Active
- 1988-08-12 DE DE3852682T patent/DE3852682T2/de not_active Expired - Lifetime
- 1988-08-12 PH PH37400A patent/PH29942A/en unknown
- 1988-08-12 ES ES88307512T patent/ES2065914T3/es not_active Expired - Lifetime
- 1988-08-12 AT AT88307512T patent/ATE116648T1/de active
- 1988-08-12 CA CA000574613A patent/CA1340083C/en not_active Expired - Lifetime
1990
- 1990-09-11 PH PH41178A patent/PH29943A/en unknown
1991
- 1991-01-28 AP AP90/00238A patent/AP9000238A0/xx unknown
1992
- 1992-12-30 LT LTRP270A patent/LT2063B/lt unknown
1995
- 1995-02-07 HU HU95P/P00072P patent/HU210815A9/hu unknown
- 1995-03-16 HK HK39595A patent/HK39595A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
LT2063B (lt)	1993-06-15
HK39595A (en)	1995-03-24
PH29943A (en)	1996-09-16
DE3852682T2 (de)	1995-06-22
US4957924A (en)	1990-09-18
ES2065914T3 (es)	1995-03-01
AP9000238A0 (en)	1991-01-31
DE19575021I2 (de)	2003-05-22
ZA885995B (en)	1990-04-25
DE3852682D1 (de)	1995-02-16
HU210815A9 (en)	1995-08-28
PH29942A (en)	1996-09-16
GB8719367D0 (en)	1987-09-23
ATE116648T1 (de)	1995-01-15
CA1340083C (en)	1998-10-13

Legal Events

Date	Code	Title	Description
2004-04-28	IF04	In force in the year 2004	Expiry date: 20080813

Publication	Publication Date	Title
DD282229A5 (de)	1990-09-05	Verfahren zur herstellung von therapeutischen acyclischen nucleosiden
DE3855333T2 (de)	1996-12-05	Therapeutische Nukleoside
DE68922903T2 (de)	1995-11-23	Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
DE3785651T2 (de)	1993-11-11	Antivirale Verbindungen.
DE3855522T2 (de)	1997-02-06	Antivirale Verbindungen
DE69426904T2 (de)	2001-10-11	Phosphonat-Nukleotid Ester-Derivate
DE69025529T2 (de)	1996-10-17	Weitere antivirale Pyrimidin-Nukleosiden
DD202717A5 (de)	1983-09-28	Antivirale purinderivate und verfahren zu ihrer herstellung
CH629206A5 (de)	1982-04-15	Verfahren zur herstellung neuer substituierter purine.
DE3852710T2 (de)	1995-05-24	Therapeutische Nukleoside.
DE3876174T2 (de)	1993-04-01	2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirus-infektionen.
DE3901502A1 (de)	1989-07-27	Didesoxydehydrocarbocyclische nucleoside
DE3887793T2 (de)	1994-07-28	5-Amino- oder substituierte Amino-1,2,3-Triazole, verwendbar als Antiproliferativa.
DE68903226T2 (de)	1993-03-04	Dideoxydidehydrocarbocyclische nukleoside.
DE69125360T2 (de)	1997-10-23	Alkylester von oxidiertem Glutathion
US5061708A (en)	1991-10-29	Therapeutic guanine esters
DE68926697T2 (de)	1996-12-12	Ester von 9-(2-Hydroxyethoxymethyl)guanin
DE2708828A1 (de)	1977-09-08	Purine, verfahren zu ihrer herstellung und pharmazeutische zubereitungen
DE3447003A1 (de)	1985-07-04	7-acylamino-9a-methoxymitosane, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
DE69118016T2 (de)	1996-08-01	Cyclobutan-Derivate
DE2708827C2 (lt)	1989-01-12
DE68914809T2 (de)	1994-08-11	Antivirale Wirkstoffe.
EP0349928A2 (de)	1990-01-10	Purinderivate
DE69429569T2 (de)	2002-09-19	Bis(hydroxymethyl)cyclopropylmethyl Pyrimidin Derivate, deren Herstellung und deren Verwendung als anti-virale Mittel
DE69307894T2 (de)	1997-06-12	Ng-monomethyl-l-arginin-hydrochlorid-derivate und verfahren zu deren herstellung